Biodexa Pharmaceuticals Plc ADR BDRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BDRX is a good fit for your portfolio.
News
-
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
-
Preliminary Results for the Year Ended 31 December 2023
-
Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
-
Biodexa Takes Aim At Type 1 Diabetes With Innovative Drug Candidate Tolimidone
-
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
-
Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
-
Biodexa Announces Allowance of U.S. Patent Covering Tolimidone
Trading Information
- Previous Close Price
- $0.72
- Day Range
- $1.14–1.74
- 52-Week Range
- $0.67–21.38
- Bid/Ask
- $1.21 / $1.23
- Market Cap
- $5.70 Mil
- Volume/Avg
- 70.8 Mil / 3.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.17
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biodexa Pharmaceuticals Plc is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 22
- Website
- https://www.biodexapharma.com
Valuation
|
Metric
|
BDRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.17 |
Price/Cash Flow | — |
Price/Earnings
BDRX
Financial Strength
|
Metric
|
BDRX
|
|---|---|
Quick Ratio | 3.18 |
Current Ratio | 3.18 |
Interest Coverage | −175.33 |
Quick Ratio
BDRX
Profitability
|
Metric
|
BDRX
|
|---|---|
Return on Assets (Normalized) | −107.02% |
Return on Equity (Normalized) | −401.56% |
Return on Invested Capital (Normalized) | −138.97% |
Return on Assets
BDRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yklydtwmmj | Fhvv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tmrtlbz | Kcwxpm | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lpltfhyvn | Zdswb | $97.8 Bil | |
MRNA
| Moderna Inc | Zdjmppbf | Yzb | $41.3 Bil | |
ARGX
| argenx SE ADR | Tvtmkbxr | Zccw | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Wpcpyvgp | Ntpzx | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Thkncxwj | Hqwssj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vndstjfb | Pwnrwb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mwwjvtrf | Vlywnjs | $12.5 Bil | |
INCY
| Incyte Corp | Vxwvrpbvl | Hpjpbn | $11.6 Bil |